Paul van der Bijl specialises in ECM transactions, public M&A, corporate governance of listed companies, anti-takeover defences and complex cross-border transactions.
Paul has acted as issuer’s counsel in the Nasdaq IPOs of Sono Motors (pending), LAVA Therapeutics, Pharvaris, CureVac, Centogene, InflaRx, trivago, Playa Hotels & Resorts, Mylan, ProQR Therapeutics and Cnova, the Euronext Amsterdam IPOs of ONWARD Medical, Unibail-Rodamco-Westfield, a.s.r., ForFarmers, Sif and Cnova and the Frankfurt Stock Exchange IPO of Instone Real Estate. He has also acted as shareholder’s counsel or underwriters’ counsel, as applicable, in the Nasdaq IPOs of ATAI Life Sciences, Merus and Affimed and the Euronext Amsterdam IPOs of Basic-Fit and Kiadis Pharma. Paul also represented AerCap in its $30.5bn acquisition of GE Capital Aviation Services and Mylan in its $22bn strategic combination with Pfizer's Upjohn division and Mylan's $7.2 billion offer for Meda.
Paul is recommended for public M&A by Legal500 and lectures on anti-takeover defences at the postgraduate specialization course of the Radboud University (Grotius).
In 2021, IFLR1000 named Paul a 'Notable practitioner' in the field of M&A. He is described by clients as 'very responsive, diligent and helpful'.